References
Key articles
Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017 Sep;124(10):1501-12.Full text Abstract
Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997 Dec;90(6):967-73. Abstract
American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 228: management of symptomatic uterine leiomyomas. Jun 2021 [internet publication].Full text
Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol. 2016 Mar;59(1):2-24.Full text Abstract
American College of Radiology. ACR Appropriateness Criteria®. Fibroids. 2022 [internet publication].Full text
Reference articles
1. Bulun SE. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344-55. Abstract
2. Bradley LD, Falcone T. Myomectomy. In: Handa VL, Van Le L, eds. Te Linde's operative gynecology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019:325-47.
3. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990 Oct;94(4):435-8. Abstract
4. Droegemueller W. Benign gynecologic conditions. In: Mishell Jr DR, Stenchever MA, Droegemueller W, et al, eds. Comprehensive gynecology, 3rd edition. St. Louis, MO: Mosby-Yearbook Inc.; 1997:467-516.
5. Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017 Sep;124(10):1501-12.Full text Abstract
6. Payson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am. 2006 Mar;33(1):1-11. Abstract
7. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997 Dec;90(6):967-73. Abstract
8. Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 Jan;188(1):100-7. Abstract
9. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 228: management of symptomatic uterine leiomyomas. Jun 2021 [internet publication].Full text
10. Townsend DE, Sparkes RS, et al. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol. 1970 Aug 15;107(8):1168-73. Abstract
11. Rein MS, Friedman AJ, Barbieri RL, et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol. 1991 Jun;77(6):923-6. Abstract
12. Mashal RD, Schoenberg-Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in leiomyomata development. Genes Chromosom Cancer. 1994 Sep;11(1):1-6. Abstract
13. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):14-8. Abstract
14. Khan KN, Kitajima M, Hiraki K, et al. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod. 2010 Nov;25(11):2878-90.Full text Abstract
15. Mäkinen N, Heinonen HR, Moore S, et al. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011 Dec;2(12):966-9.Full text Abstract
16. Chang HL, Senaratne TN, Zhang L, et al. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci. 2010 Feb;17(2):158-67.Full text Abstract
17. Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17053-8.Full text Abstract
18. Omar M, Laknaur A, Al-Hendy A, et al. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. BMC Womens Health. 2019 Jul 9;19(1):92.Full text Abstract
19. Yang Q, Ali M, El Andaloussi A, et al. The emerging spectrum of early life exposure-related inflammation and epigenetic therapy. Cancer Stud Mol Med. 2018 Nov;4(1):13-23.Full text Abstract
20. Yang Q, Al-Hendy A. Developmental environmental exposure alters the epigenetic features of myometrial stem cells. Gynecol Obstet Res. 2016 Dec;3(2):e1-e4.Full text Abstract
21. Leppert PC, Catherino WH, Segars JH, et al. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol. 2006 Aug;195(2):415-20. Abstract
22. Patterson-Keels LM, Selvaggi SM, Haefner HK, et al. Morphologic assessment of endometrium overlying submucosal leiomyomas. J Reprod Med. 1994 Aug;39(8):579-84. Abstract
23. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981 Oct;36(4):433-45. Abstract
24. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Human Repr Update. 1996 Jul-Aug;2(4):295-306. Abstract
25. Ross RK, Pike MC, Vessey, MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986 Aug 9;293(6543):359-62. Abstract
26. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003 Jun;111(8):1037-54.Full text Abstract
27. Wise LA, Palmer JR, Stewart EA, et al. Age-specific incidence rates for self-reported uterine leiomyomata in the black women's health study. Obstet Gynecol. 2005 Mar;105(3):563-8. Abstract
28. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epid. 2001 Jan 1;153(1):1-10. Abstract
29. Oskovi Kaplan ZA, Taşçi Y, Topçu HO, et al. 25-Hydroxy vitamin D levels in premenopausal Turkish women with uterine leiomyoma. Gynecol Endocrinol. 2018 Mar;34(3):261-4. Abstract
30. Al-Hendy A, Diamond MP, Boyer TG, et al. Vitamin D3 inhibits Wnt/β-catenin and mTOR signaling pathways in human uterine fibroid cells. J Clin Endocrinol Metab. 2016 Apr;101(4):1542-51.Full text Abstract
31. Boynton-Jarrett R, Rich-Edwards J, Malspeis S, et al. A prospective study of hypertension and risk of uterine leiomyomata. Am J Epidemiol. 2005 Apr 1;161(7):628-38. Abstract
32. Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol. 2016 Mar;59(1):2-24.Full text Abstract
33. Templeman C, Marshall SF, Clarke CA, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril. 2009 Oct;92(4):1436-46.Full text Abstract
34. Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015 Apr 23;372(17):1646-55. Abstract
35. Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004 Jan 15;159(2):113-23. Abstract
36. Ciebiera M, Ali M, Zgliczyńska M, et al. Vitamins and uterine fibroids: current data on pathophysiology and possible clinical relevance. Int J Mol Sci. 2020 Aug 1;21(15):5528.Full text Abstract
37. Wise LA, Radin RG, Palmer JR, et al. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr. 2011 Dec;94(6):1620-31.Full text Abstract
38. Chiaffarino F, Parazzini F, La Vecchia C, et al. Diet and uterine myomas. Obstet Gynecol. 1999 Sep;94(3):395-8. Abstract
39. Maruo T, Ohara N, Wang J, et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004 May-Jun;10(3):207-20. Abstract
40. Chiaffarino F, Ricci E, Cipriani S, et al. Cigarette smoking and risk of uterine myoma: systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:63-71. Abstract
41. Pavone D, Clemenza S, Sorbi F, et al. Epidemiology and risk factors of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:3-11. Abstract
42. Chiaffarino F, Cipriani S, Ricci E, et al. Alcohol consumption and risk of uterine myoma: a systematic review and meta analysis. PLoS One. 2017;12(11):e0188355.Full text Abstract
43. American College of Radiology. ACR Appropriateness Criteria®. Fibroids. 2022 [internet publication].Full text
44. American College of Radiology. ACR appropriateness criteria: clinically suspected adnexal mass, no acute symptoms. 2023 [internet publication].Full text
45. Critchley HO, Warner P, Less AJ, et al. Evaluation of abnormal bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Tech Assess. 2004 Sep;8(34):iii-iv, 1-139. Abstract
46. Hatasaka H. The evaluation of abnormal uterine bleeding. Clin Obstet Gynecol. 2005 Jun;48(2):258-73. Abstract
47. Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol. 1991 May;77(5):745-8. Abstract
48. American Congress of Obstetricians and Gynecologists. ACOG practice bulletin number 65: management of endometrial cancer. Obstet Gynecol. 2006 Apr;107(4):952. Abstract
49. DiSaia PJ, Creasman WT. Clinical gynecologic oncology, 6th ed. St Louis, MO: Mosby, Inc.; 2002:137-71.
50. Creasman WT. Malignant tumors of the uterine corpus. In: Rock JA, Jones III HW, eds. Te Linde's operative gynecology, 9th ed. Philadelphia, PA: JB Lippincott Co.; 2003:1445-86.
51. Clevenger-Hoeft M, Syrop CH, Stovall DW. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999 Oct;94(4):516-20. Abstract
52. American Congress of Obstetricians and Gynecologists. Technology assessment: saline infusion sonohysterography. Int J Gynaecol Obstet. 2004 Jan;84(1):95-8. Abstract
53. Cicinelli E, Romano F, Anastasio PS, et al. Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas. Obstet Gynecol. 1995 Jan;85(1):42-7. Abstract
54. Dueholm M, Lundorf E, Olesen F. Imaging techniques for evaluation of the uterine cavity and endometrium in premenopausal patients before minimally invasive surgery. Obstet Gynecol Survey. 2002 Jun;57(6):388-403. Abstract
55. Leone FP, Lanzani C, Ferrazzi E. Use of strict sonohysterographic methods for preoperative assessment of submucous myomas. Fertil Steril. 2003 Apr;79(4):998-1002. Abstract
56. Davis PC, O'Neill MJ, Yoder IC, et al. Sonohysterographic findings of endometrial and subendometrial conditions. Radiographics. 2002 Jul-Aug;22(4):803-16. Abstract
57. Gaucherand P, Piacenza JM, Salle B, et al. Sonohysterography of the uterine cavity: preliminary investigations. J Clin Ultrasound. 1995 Jul-Aug;23(6):339-48. Abstract
58. Alatas C, Aksoy E, Akarsu C, et al. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997 Mar;12(3):487-90. Abstract
59. Nieuwenhuis LL, Hermans FJ, Bij de Vaate AJM, et al. Three-dimensional saline infusion sonography compared to two-dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions. Cochrane Database Syst Rev. 2017 May 5;5:CD011126.Full text Abstract
60. Bittencourt CA, Dos Santos Simões R, Bernardo WM, et al. Accuracy of saline contrast sonohysterography in detection of endometrial polyps and submucosal leiomyomas in women of reproductive age with abnormal uterine bleeding: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017 Jul;50(1):32-9.Full text Abstract
61. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. May 2021 [internet publication].Full text
62. American College of Obstetricians and Gynecologists. Committee opinion no. 800: the use of hysteroscopy for the diagnosis and treatment of intrauterine pathology. Mar 2020 [internet publication].Full text
63. Thomassin-Naggara I, Daraï E, Nassar-Slaba J, et al. Value of dynamic enhanced magnetic resonance imaging for distinguishing between ovarian fibroma and subserous uterine leiomyoma. J Comput Assist Tomogr. 2007 Mar-Apr;31(2):236-42. Abstract
64. Maizlin ZV, Vos PM, Cooperberg PL. Is it a fibroid? Are you sure? Sonography with MRI assistance. Ultrasound. 2007 Mar;23(1):55-62. Abstract
65. Wolfman DJ, Ascher SM. Magnetic resonance imaging of benign uterine pathology. Top Magn Reson Imaging. 2006 Dec;17(6):399-407. Abstract
66. Macura KJ. Role of magnetic resonance imaging in the assessment of the female pelvis. Top Magn Reson Imaging. 2006 Dec;17(6):363-4.
67. Curtis M, Hopkins MP, Zarlingo T, et al. Magnetic resonance imaging to avoid laparotomy in pregnancy. Obstet Gynecol. 1993 Nov;82(5):833-6. Abstract
68. Kido AK, Togashi K, Koyama T, et al. Diffusely enlarged uterus: evaluation with MR imaging. Radiographics. 2003 Nov-Dec;23(6):1423-39. Abstract
69. Zhang M, Wasnik AP, Masch WR, et al. Transvaginal ultrasound shear wave elastography for the evaluation of benign uterine pathologies: a prospective pilot study. J Ultrasound Med. 2019 Jan;38(1):149-55.Full text Abstract
70. Stoelinga B, Hehenkamp WJK, Nieuwenhuis LL, et al. Accuracy and reproducibility of sonoelastography for the assessment of fibroids and adenomyosis, with magnetic resonance imaging as reference standard. Ultrasound Med Biol. 2018 Aug;44(8):1654-63. Abstract
71. Stewart EA, Taran FA, Chen J, et al. Magnetic resonance elastography of uterine leiomyomas: a feasibility study. Fertil Steril. 2011 Jan;95(1):281-4.Full text Abstract
72. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004 Aug;104(2):393-406. Abstract
73. Broder MS, Goodwin S, Chen G, et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol. 2002 Nov;100(5 Pt 1):864-8. Abstract
74. Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Survey. 2001 Aug;56(8):483-91. Abstract
75. Sanders B. Uterine factors and infertility. J Reprod Med. 2006 Mar;51(3):169-76. Abstract
76. Critchley HOD, Warner P, Less AJ, et al. Evaluation of abnormal bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Tech Assess. 2004;8:1-46. Abstract
77. Salem S. The uterus and adnexa. In: Rumack CM, Wilson SR, Charboneau JW, eds. Diagnostic ultrasound. 2nd ed. Philadelphia, PA: Mosby-Year Book Inc.; 1998:519-73.
78. Jondal DE, Wang J, Chen J, et al. Uterine fibroids: correlations between MRI appearance and stiffness via magnetic resonance elastography. Abdom Radiol (NY). 2018 Jun;43(6):1456-63.Full text Abstract
79. Vitiello D, McCarthy S. Diagnostic imaging of myomas. Obstet Gynecol Clin North Am. 2006 Mar;33(1):85-95. Abstract
80. Chambers JT, Chambers SK. Endometrial sampling: When? Where? Why? With what? Clin Obstet Gynecol. 1992 Mar;35(1):28-39. Abstract
81. Rajkotia K, Veeramani M, Macura KJ. Magnetic resonance imaging of adnexal masses. Top Magn Reson Imaging. 2006 Dec;17(6):379-97. Abstract
82. Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of uterine fibroids: comparative effectiveness review No. 195. AHRQ publication no. 17(18)-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2017. \Full text
83. US Food and Drug Administration. FDA updated assessment of the use of laparoscopic uterine power morcellators to treat uterine fibroids. Dec 2017 [internet publication].Full text
84. American College of Obstetricians and Gynecologists. Committee opinion no. 822: uterine morcellation for presumed leiomyomas. Mar 2021 [internet publication].Full text
85. Tropeano G, Amoroso S, Scambia G. Non-surgical management of uterine fibroids. Hum Reprod Update. 2008 May-Jun;14(3):259-74.Full text Abstract
86. Cheng MH, Wang PH. Uterine myoma: a condition amenable to medical therapy? Expert Opin Emerg Drugs. 2008 Mar;13(1):119-33. Abstract
87. Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011 Feb;112(2):126-30. Abstract
88. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol. 2004 Jun;16(3):239-43. Abstract
89. Morris EP, Rymer J, Robinson J, et al. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril. 2008 Feb;89(2):421-8. Abstract
90. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):307-31. Abstract
91. Chwalisz K, Garg R, Brenner R, et al. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006;4 (suppl 1):S8.Full text Abstract
92. Sabry M, Al-Hendy A. Medical treatment of uterine leiomyoma. Reprod Sci. 2012 Apr;19(4):339-53.Full text Abstract
93. Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003 May;79(5):1194-8. Abstract
94. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS): a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):9-28. Abstract
95. Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020 Jan 23;382(4):328-40.Full text Abstract
96. Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017 Jul;108(1):152-60.e4.Full text Abstract
97. Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019 Aug;55(8):503-12. Abstract
98. Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019 Mar;133(3):423-33.Full text Abstract
99. Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021 Feb 18;384(7):630-42.Full text Abstract
100. Rodriguez MB, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019 Sep 19;9(9):CD000400.Full text Abstract
101. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991 Mar;164(3):879-83. Abstract
102. Ip PP, Lam KW, Cheung CL, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol. 2007 Aug;31(8):1215-24. Abstract
103. Peitsidis P, Koukoulomati A. Tranexamic acid for the management of uterine fibroid tumors: a systematic review of the current evidence. World J Clin Cases. 2014 Dec 16;2(12):893-8.Full text Abstract
104. Jin C, Hu Y, Chen XC, et al. Laparoscopic versus open myomectomy: a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2009 Jul;145(1):14-21. Abstract
105. Davis MR, Soliman AM, Castelli-Haley J, et al. Reintervention rates after myomectomy, endometrial ablation, and uterine artery embolization for patients with uterine fibroids. J Womens Health (Larchmt). 2018 Oct;27(10):1204-14.Full text Abstract
106. Kongnyuy EJ, van den Broek N, Wiysonge CS. A systematic review of randomized controlled trials to reduce hemorrhage during myomectomy for uterine fibroids. Int J Gynaecol Obstet. 2008 Jan;100(1):4-9. Abstract
107. Iverson RE Jr, Chelmow D, Strohbehn K, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol. 1996 Sep;88(3):415-9. Abstract
108. Lefebvre G, VIlos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2003 May;25(5):396-418. Abstract
109. Herrmann A, De Wilde R L. Laparoscopic myomectomy—the gold standard. Gynecol Minim Invasive Ther. 2014 May;3(2):31-8.Full text
110. Ming X, Ran XT, Li N, et al. Risk of recurrence of uterine leiomyomas following laparoscopic myomectomy compared with open myomectomy. Arch Gynecol Obstet. 2020 Jan;301(1):235-42. Abstract
111. Kotani Y, Tobiume T, Fujishima R, et al. Recurrence of uterine myoma after myomectomy: open myomectomy versus laparoscopic myomectomy. J Obstet Gynaecol Res. 2018 Feb;44(2):298-302.Full text Abstract
112. Laveaux SM, Advincula AP. Robot-assisted laparoscopic myomectomy (RALM). In: El-Ghobashy A, Ind T, Persson J, et al, eds. Textbook of gynecologic robotic surgery. Cham: Springer; 2018.
113. Lonnerfors C. Robot-assisted myomectomy. Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:113-9. Abstract
114. Iavazzo C, Mamais I, Gkegkes ID. Robotic assisted vs laparoscopic and/or open myomectomy: systematic review and meta-analysis of the clinical evidence. Arch Gynecol Obstet. 2016 Jul;294(1):5-17. Abstract
115. Behbehani S, Suarez-Salvador E, Buras M, et al. Mortality rates in benign laparoscopic and robotic gynecologic surgery: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2020 Mar-Apr;27(3):603-12.e1. Abstract
116. Sheu BC, Huang KJ, Huang SC, et al. Comparison of uterine scarring between robot-assisted laparoscopic myomectomy and conventional laparoscopic myomectomy. J Obstet Gynaecol. 2020 Oct;40(7):974-980. Abstract
117. Unger CA, Lachiewicz MP, Ridgeway B. Risk factors for robotic gynecologic procedures requiring conversion to other surgical procedures. Int J Gynaecol Obstet. 2016 Dec;135(3):299-303. Abstract
118. Dubuisson JB, Fauconnier A, Fourchotte V, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod. 2001 Aug;16(8):1726-31.Full text Abstract
119. American College of Obstetricians and Gynecologists. Committee opinion no. 810: robot-assisted surgery for noncancerous gynecologic conditions. Sep 2020 [internet publication].Full text
120. Fernandez H, Sefrioui O, Virelizier C, et al. Hysteroscopic resection of submucosal myomas in patients with infertility. Hum Reprod. 2001 Jul;16(7):1489-92. Abstract
121. Bajekal N, Li TC. Fibroids, infertility and pregnancy wastage. Hum Reprod Update. 2000 Nov-Dec;6(6):614-20. Abstract
122. Di Spiezio Sardo A, Mazzon I, Bramante S, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update. 2008 Mar-Apr;14(2):101-19.Full text Abstract
123. American Association of Gynecologic Laparoscopists (AAGL): Advancing Minimally Invasive Gynecology Worldwide. AAGL practice report: practice guidelines for the diagnosis and management of submucous leiomyomas. J Minim Invasive Gynecol. 2012 Mar-Apr;19(2):152-71. Abstract
124. Emanuel MH, Hart A, Wamsteker K, et al. An analysis of fluid loss during transcervical resection of submucous myomas. Fertil Steril. 1997 Nov;68(5):881-6.Full text Abstract
125. Royal College of Obstetricians and Gynaecologists (RCOG); British Society for Gynaecological Endoscopy. Best practice in outpatient hysteroscopy. Green-top guideline no. 59. Mar 2011 [internet publication].Full text
126. American Congress of Obstetricians and Gynecologists. ACOG committee opinion: uterine artery embolization. Obstet Gynecol. 2004 Feb;103(2):403-4. Abstract
127. Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril. 2010 Jun;94(1):324-30. Abstract
128. Carranza-Mamane B, Havelock J, Hemmings R, et al; Society of Obstetricians and Gynaecologists of Canada. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can. 2015 Mar;37(3):277-85.Full text Abstract
129. Gupta JK, Sinha A, Lumsden MA, et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2014 Dec 26;(12):CD005073.Full text Abstract
130. Royal College of Obstetricians and Gynaecologists; Royal College of Radiologists. Clinical recommendations on the use of uterine artery embolisation (UAE) in the management of fibroids. Dec 2013 [internet publication].Full text
131. El Shamy T, Amer SAK, Mohamed AA, et al. The impact of uterine artery embolization on ovarian reserve: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2020 Jan;99(1):16-23.Full text Abstract
132. American College of Obstetricians and Gynecologists. Committee opinion no. 628: robotic surgery in gynecology. Obstet Gynecol. 2015 Mar;125(3):760-7. Abstract
133. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 444: choosing the route of hysterectomy for benign disease. Obstet Gynecol. 2009 Nov;114(5):1156-8. Abstract
134. AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL position statement: route of hysterectomy to treat benign uterine disease. J Minim Invasive Gynecol. 2011 Jan-Feb;18(1):1-3. Abstract
135. Lawrie TA, Liu H, Lu D, et al. Robot-assisted surgery in gynaecology. Cochrane Database Syst Rev. 2019 Apr 15;4:CD011422.Full text Abstract
136. Martínez-Maestre MA, Gambadauro P, González-Cejudo C, et al. Total laparoscopic hysterectomy with and without robotic assistance: a prospective controlled study. Surg Innov. 2014 Jun;21(3):250-5. Abstract
137. Paraiso MF, Ridgeway B, Park AJ, et al. A randomized trial comparing conventional and robotically assisted total laparoscopic hysterectomy. Am J Obstet Gynecol. 2013 May;208(5):368.e1-7. Abstract
138. Sarlos D, Kots L, Stevanovic N, et al. Robotic compared with conventional laparoscopic hysterectomy: a randomized controlled trial. Obstet Gynecol. 2012 Sep;120(3):604-11.Full text Abstract
139. Swenson CW, Kamdar NS, Harris JA, et al. Comparison of robotic and other minimally invasive routes of hysterectomy for benign indications. Am J Obstet Gynecol. 2016 Nov;215(5):650.e1-e8.Full text Abstract
140. Lönnerfors C, Reynisson P, Persson J. A randomized trial comparing vaginal and laparoscopic hysterectomy vs robot-assisted hysterectomy. J Minim Invasive Gynecol. 2015 Jan;22(1):78-86. Abstract
141. Bogliolo S, Ferrero S, Cassani C, et al. Single-site versus multiport robotic hysterectomy in benign gynecologic diseases: a retrospective evaluation of surgical outcomes and cost analysis. J Minim Invasive Gynecol. 2016 May-Jun;23(4):603-9. Abstract
142. Metwally M, Raybould G, Cheong YC, et al. Surgical treatment of fibroids for subfertility. Cochrane Database Syst Rev. 2020 Jan 29;(1):CD003857.Full text Abstract
143. Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015 Aug 12;(8):CD003677.Full text Abstract
144. European Medicines Agency. Ulipristal acetate for uterine fibroids: EMA recommends restricting use. Jan 2021 [internet publication].Full text
145. Medicines and Healthcare products Regulatory Agency. Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury. Feb 2021 [internet publication].Full text
146. European Medicines Agency. Esmya: new measures to minimise risk of rare but serious liver injury. Aug 2018 [internet publication].Full text
147. European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. 13 Mar 2020 [internet publication].Full text
148. Medicines and Healthcare products Regulatory Agency. Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury. Mar 2020 [internet publication].Full text
149. European Medicines Agency. PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids. Sep 2020 [internet publication].Full text
150. Magnay JL. Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids. Fertil Steril. 2019 Feb;111(2):249-50.Full text Abstract
151. Atkinson D. Hormonal therapy before surgery for uterine fibroids. Am J Nurs. 2018 Nov;118(11):19.Full text Abstract
152. Hilário SG, Bozzini N, Borsari R, et al. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril. 2009 Jan;91(1):240-3.Full text Abstract
153. Gurates B, Parmaksiz C, Kilic G, et al. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008 Oct;17(4):569-74.Full text Abstract
154. Song H, Lu D, Navaratnam K, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013 Oct 23;(10):CD009505.Full text Abstract
155. Sadan O, Ginath S, Sofer D, et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata -- a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001 Jun;96(2):183-6. Abstract
156. Deng L, Wu T, Chen XY, et al. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2012 Oct 17;10:CD005287.Full text Abstract
157. Yoon SW, Lee C, Cha SH, et al. Patient selection guidelines in MR-guided focused ultrasound surgery of uterine fibroids: a pictorial guide to relevant findings in screening pelvic MRI. Eur Radiol. 2008 Dec;18(12):2997-3006. Abstract
158. Kröncke T, David M. MR-guided focused ultrasound in fibroid treatment - results of the 4th radiological-gynecological expert meeting. Rofo. 2019 Jul;191(7):626-9.Full text Abstract
159. Jacoby AF. New and emerging treatments for uterine leiomyomas. Adv Stud Med. 2006;6(6):260-6.
160. Zhang Y, Peng W, Clarke J, et al. Acupuncture for uterine fibroids. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007221.Full text Abstract
161. Hajhashemi M, Ansari M, Haghollahi F, et al. The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency. Caspian J Intern Med. 2019 Spring;10(2):125-31.Full text Abstract
162. Liu JP, Yang H, Xia Y, et al. Herbal preparations for uterine fibroids. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD005292.Full text Abstract
163. Roshdy E, Rajaratnam V, Maitra S, et al. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health. 2013;5:477-86.Full text Abstract
164. National Institute for Health and Care Excellence. Uterine artery embolisation for fibroids. Nov 2010 [internet publication].Full text
165. Li TC, Mortimer R, Cook ID. Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Human Repro. 1999 Jul;14(7):1735-40. Abstract
166. Vilos GA, Allaire C, Laberge PY, et al; Special Contributors. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015 Feb;37(2):157-78.Full text Abstract
167. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor and delivery, with uterine leiomyomas: a population-based study. Obstet Gynecol. 2000 May;95(5):764-9. Abstract
168. Practice Committee of the American Society for Reproductive Medicine. Myomas and reproductive function. Fertil Steril. 2006 Nov;86(5 Suppl 1):S194-9. Abstract
169. Casini ML, Rossi F, Agostini R, et al. Effects of the position of fibroids on fertility. Gynecol Endocrinol. 2006 Feb;22(2):106-9. Abstract
Use of this content is subject to our disclaimer